Amniotics has an approved GMP manufacturing facility to produce Advanced therapy medicinal products (ATMPs), and is looking to establish strategic partnerships with researchers and companies interested in developing stem-cell-based therapies targeting diseases with high unmet needs. The company is uniquely positioned to translate stem cell technologies into novel and improved human therapeutics, and is committed to providing the best cell therapeutics for treatments with high unmet needs in collaboration with international renowned KOLs and partners.